Please note Epocrates will no longer provide this CME offering after December 31, 2015. However this free offering will continue to be available directly from RealCME and there will be no interruption to your account, including credits, certificates and new course offerings.

Please directly access your account by clicking RealCME Health Professional and use the same email address to log in to your account that you have used with EpocratesCME. For security purposes, you will be asked to establish a new password.

Donald Visits 1 - 2: A 62-year-old man with chronic gout and comorbidities


Donald Visits 1 - 2: A 62-year-old man with chronic gout and comorbidities

Topic: Rheumatology
Relevant Terms: Diabetes Mellitus, Hypertension, Lipid Disorders, Metabolic Syndrome
Primary Audience: Primary Care clinicians (Family Practice; General Practitioner; internal medicine; Nurse Practitioner & Physician Assistant) involved in treating and managing patients who present with gout.
Launch Date: 19-Nov-12
Credits: 0.5 AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Gout -- Optimizing Disease Management

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Provide more effective therapy for gout by initiating uric acid lowering therapy when needed and monitoring uric acid levels at appropriate intervals.
  2. Assess current recommendations for the use of short-term anti-inflammatory agents to prevent gout flares when initiating uric acid lowering therapy.
  3. Evaluate patients with gout for the presence of co-morbidities and tailor management strategies accordingly.
  4. Develop counseling, education, and practice management strategies that promote better patient adherence to long-term therapies for gout.


    Paul R. Esserman Professor of Medicine
    Director, NYU-HHC Clinical and Translational Science Institute
    Associate Director for Research, Department of Medicine
    Director, Division of Translational Medicine
    NYU School of Medicine
    New York, NY
    Associate Professor of Medicine, Biochemistry and Molecular Pharmacology
    Director of Rheumatology Training
    New York University School of Medicine / NYU Langone Medical Center
    Rheumatology Section Chief
    New York Harbor Health Care System, New York Campus
    United States Department of Veterans Affairs
    New York, NY

    Jointly Sponsored by NYU Post-Graduate Medical School and DKBmed, LLC.

    Accreditation Statement
    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of NYU Post-Graduate Medical School and DKBmed, LLC. NYU Post-Graduate Medical School is accredited by the ACCME to provide continuing medical education for physicians.
    Credit Designation Statement
    The NYU Post-Graduate Medical School designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Method of Participation
    There are no fees for participating in this CME activity. To receive credit, participants must (1) read all of the CME accreditation information (2) complete the educational activity, and (3) complete the post-test and activity evaluation form, including the certificate information section. This should take 30 minutes of your time.

    To take the post-test for Gout ODM:Optimizing Disease Management you will need to click here, and have a passing grade of 70% or higher on the post-test to receive credit.

    Date of release: November 19, 2012
    Expiration date: November 18, 2013

    Target Audience
    Primary Care clinicians (Family Practice, General Practitioner, Internal Medicine, Nurse Practitioner & Physician Assistant) involved in treating and managing patients who present with gout.
    Course Description
    Gout ODM has been developed by the New York University Post-Graduate Medical School (NYU PGMS) for primary care clinicians to address key practice and knowledge gaps that have resulted in suboptimal care in patients who present with gout. This multi-phased, program-level initiative incorporates learner-preferred methodologies in its design, including problem-based learning, interactive techniques, and patient simulations.

    Statement of Need
    Through a review of the current literature, including national and regional measures, detailed conversations with expert educators, and a 2011 survey of potential program participants, this program will address the following core patient care gaps:
    • Primary care clinicians often fail to choose appropriate therapies for gout and do not monitor whether patients have achieved target uric acid levels.
    • Primary care clinicians often do not provide prophylaxis to prevent painful gout flare-ups that can occur when initiating chronic uric acid-lowering therapy.
    • Gout management is complicated by the frequent presence of co-morbidities, such as hypertension, lipid disorders, and diabetes mellitus.
    • Patient adherence to ongoing gout treatment and lifestyle changes is very low compared with other chronic diseases, requiring significant commitment on the part of the clinician to education and counseling.
    Disclosure Statement
    The NYU Post-Graduate Medical School adheres to ACCME Essential Areas and policies, including the Standards for Commercial Support regarding industry support of continuing medical education. In order to resolve any identified Conflicts of Interest, disclosure information is provided during the planning process to ensure resolution of any identified conflicts. Disclosure of faculty and commercial relationships as well as the discussion of unlabeled or unapproved use of any drug, device or procedure by the faculty is listed on the following page.

    Full Disclosure Policy
    It is the policy of the NYU Post Graduate Medical School to insure balance, independence, objectivity, and scientific rigor in all its individually sponsored or jointly sponsored activities. Because CME activities are conducted in the public interest, it is important to assure the public that education received by physicians and other health care professionals through whom patient care decisions are made is conducted with the highest integrity, scientific objectivity and in the absence of bias. A conflict of interest exists when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the product or services of that commercial interest. The Accreditation Council for Continuing Medical Education (ACCME) holds providers of CME responsible for collecting information from its instructors, planners and managers of CME content and resolving those conflicts prior to the commencement of the CME activity. The intent of the conflict of interest resolution process is to assure that provider, faculty and planner financial relationships with commercial interests and resultant loyalties do not supersede the public interest in the design and delivery of continuing medical education activities for the profession.

    The following have indicated whether or not they have received financial support for consultation, research or evaluation, have a financial interest relative to their presentation or will include the discussion of the unlabeled or unapproved use of a drug, device or procedure:
    Planner and Presenter Disclosure
    Dr. Bruce N. Cronstein (Planner and Presenter)
    Dr. Cronstein has received research grants from Takeda Pharmaceuticals and OSI Pharmaceuticals, LLC. He has also served as a consultant for Bristol-Myers Squibb, Novartis Pharmaceuticals, Can-Fite BioPharma Ltd., Cypress Laboratories, Regeneron Pharmaceuticals, Inc., Endocyte, Inc., Protalex, Inc., Allos, Inc., Savient Pharmaceuticals, Inc., Gismo Therapeutics, Inc., Antares Pharma, Inc., and MediVector, Inc, and numerous intellectual properties.

    Dr. Michael H. Pillinger (Planner and Presenter)
    Dr. Pillinger is a site investigator for a study being conducted by, and has also received an investigator-initiated research grant from Takeda Pharmaceuticals. He has also served as a consultant for Savient Pharmaceuticals. His presentation will include discussion of the unlabeled or unapproved use of a drug, medical device or procedure; i.e., phase 3 studies of Canakinumab and Rilonacept.

    Norman Sussman, MD (Associate Dean for Postgraduate Programs and Planner)
    Reports no relevant financial relationships.

    Deal Beals (President & CEO of DKBmed, LLC and Planner)
    Reports no relevant financial relationships.

    The Independent Reviewer of this activity reports no relevant financial relationships.

    General Information
    Copyright Information: All rights are reserved. No part of this program may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews. All rights reserved - The New York University Post-Graduate Medical School and DKBmed, LLC.

    Acknowledgement of Commercial Support
    This course is supported in part by independent medical education grants from: Regeneron Pharmaceuticals, Inc, Savient Pharmaceuticals, Inc, and Takeda Pharmaceuticals International, Inc.

    To view the activity online you will need the following hardware/software: Personal computer or smartphone with internet access, and one of the following web browsers: Google Chrome for Windows, Mac, or Linux; Internet Explorer 7.0+ for Windows; Mozilla 1.4+ for Windows, Mac, or Linux; Firefox 3.5+ for Windows, Mac, or Linux; or Safari 4.0+ for Mac. Monitor settings: High color at 800 x 600 pixels

    For questions concerning CME certification, contact Joann Carpana, 212-263-5292 or

    For further information about NYU's privacy and confidentiality policy visit:

    For technical problems send email to,